Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus in breast cancer-related lymphedema
NCT04541290Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Envarsus XR in breast cancer-related lymphedema (BCRL), sponsored by University Hospital Odense. Primary endpoint: Change in Arm volume measured with water displacement test at 12 months. Started Sep 2020; status: completed.
02
Drugs
Envarsus XR
03
Conditions
breast cancer-related lymphedema (BCRL)
Beyond the preview
Go deeper on NCT04541290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541290.